Life Sciences

  • April 14, 2026

    Eli Lilly To Purchase Cooley-Led CrossBridge In $300M Deal

    Venture-backed pre-clinical biotechnology firm CrossBridge Bio Inc., advised by Cooley LLP, on Tuesday announced that it has agreed to be bought by pharmaceutical giant Eli Lilly & Co. in a deal worth up to $300 million.

  • April 14, 2026

    Mich. AG Says PBMs Can't Duck Drug-Pricing Suit

    Two pharmacy benefit managers can't dodge an antitrust lawsuit accusing them of price-fixing reimbursement rates because Michigan has properly claimed an antitrust violation, state Attorney General Dana Nessel told a federal court, asking it to toss aside the PBMs' dismissal bid. 

  • April 14, 2026

    4th Circ. Won't Rehear Allergan Overcharge Suit

    The Fourth Circuit on Tuesday denied a rehearing petition lodged after a panel revived a whistleblower suit accusing an Allergan Sales LLC predecessor of overcharging Medicaid.

  • April 14, 2026

    Buyers Seek Final Approval Of $4.85M Bayer Benzene Deal

    A class of consumers is asking a New Jersey federal court to give final approval of a $4.85 million settlement to resolve claims that Bayer US LLC's antifungal products were contaminated with benzene.

  • April 14, 2026

    Avanos Medical Going Private In $1.3B Deal Led By 3 Firms

    American Industrial Partners has agreed to acquire Avanos Medical Inc. in an all-cash transaction valued at nearly $1.3 billion, a take-private deal steered by three law firms, Avanos announced Tuesday. 

  • April 14, 2026

    State AGs, Albertsons Chain Reach $773M Opioid Deal

    Albertsons Cos. Inc. and the attorneys general of California, Colorado, Illinois and Oregon on Tuesday said that the pharmacy and grocery chain had agreed to a $773 million settlement in principle to end claims brought by states, local governments and Native American tribes over its role in the opioid crisis.

  • April 14, 2026

    Omnicare OK'd For Ch. 11 Auction With $250M Base Bid

    Pharmacy services provider Omnicare's choice of a $250 million stalking horse bid for its assets was approved Tuesday by a Texas bankruptcy judge, setting up a possible auction in May.

  • April 13, 2026

    Oracle Wins TRO Against Ex-Worker Threatening Secrets Sale

    A North Carolina federal judge Monday issued a temporary restraining order barring a recently laid-off Oracle sales employee from disclosing trade secrets that the software firm alleges he has threatened to sell to the "highest bidder" unless he receives an "unreasonable" fee.

  • April 13, 2026

    Citron's 'Shadowy Gang' Sued Over Short Selling Campaign

    Shareholders of PolarityTE have alleged in a new suit that "members of a shadowy gang of short sellers" conspired to short the biotechnology company's stock through targeted negative media attacks with Citron Research to enrich themselves at the expense of the shareholders, and that they ultimately caused the company's bankruptcy.

  • April 13, 2026

    Ill. Judge Wants More Proof To Recalculate Kickback Damages

    An Illinois federal judge tasked with recalculating damages from a home health company's referral kickback scheme said Monday that she needs more complete and reliable evidence to help determine the appropriate amount, but allowed the government to continue offsetting Medicare payments as part of its judgment collection bid.

  • April 13, 2026

    FTC Ends Teen Height Growth Supplement Claims

    A supplement maker and its owners agreed to pay $750,000 to end claims they misled customers into thinking their products could make their children taller, the Federal Trade Commission announced on Monday.

  • April 13, 2026

    Del. Judge Ends 80K Pre-2026 Zantac Cases

    A Delaware state court on Monday dismissed more than 80,000 suits filed before December alleging that Boehringer Ingelheim's discontinued heartburn medication Zantac caused cancer, following a Delaware Supreme Court ruling on admissibility of the plaintiffs' experts.

  • April 13, 2026

    Obesity Drugmaker Leads 2 Biotech Startups Eyeing IPOs

    Two biotechnology startup companies on Monday filed plans for their public debuts, with obesity-focused Kailera Therapeutics planning to raise an estimated $500 million in its initial public offering and protein biomarker detection platform Alamar Biosciences planning to raise around $150 million.

  • April 13, 2026

    Mylan Can't Revive Copaxone Antitrust Claims Against Teva

    A New Jersey federal judge sided Monday with a special master's recommendations to nix some of the parallel claims from Mylan and retailers like Walgreens accusing Teva of using regulatory deception, false advertising, improper rebates and more to delay generic competition to its Copaxone multiple sclerosis treatment.

  • April 13, 2026

    Hikma Tells Justices Cox Ruling Boosts 'Skinny Label' Case

    Hikma Pharmaceuticals USA Inc. told the U.S. Supreme Court on Monday that the justices' recent decision clearing an internet company in a copyright case bolsters the drugmaker's challenge to a patent suit over its generic version of an Amarin Pharma Inc. heart drug.

  • April 13, 2026

    VC Apple Tree Seeks $7M As Judge Mulls Ch. 11 Funding Fight

    Biotech investor Apple Tree Life Sciences Inc. asked a Delaware bankruptcy judge to let it use $7 million from a larger funding motion she has yet to rule on, saying it needs the money for operating expenses and drug development costs.

  • April 13, 2026

    AI Cardiac Imaging Co. Hits Ex-Consultant With IP Suit

    Artificial intelligence-powered cardiac imaging company Heartflow Inc. filed patent infringement and trade secret misappropriation claims on Monday against a competitor founded by a former consultant who, the company says, lifted technological trade secrets while he was under contract.

  • April 13, 2026

    Inventors Face Bayh-Dole Act Reporting Issues, GAO Says

    Universities and businesses that hold on to patent rights after receiving federal funds for developing the inventions have pointed to problems with the reporting requirements, according to the U.S. Government Accountability Office.

  • April 13, 2026

    Texas GLP-1 Compounder Caused Mom's Death, Family Says

    A Houston compounding pharmacy misled consumers by marketing its weight loss and diabetes drugs as safe and pharmaceutical-grade while selling contaminated medicines, a deceased Texas woman's family claims in a wrongful death lawsuit, alleging the drugs led to the woman's death. 

  • April 13, 2026

    11th Circ. Backs FDA's Ban Over Drug Tester's Conviction

    The Eleventh Circuit on Monday backed a U.S. Food and Drug Administration order barring a former pharmaceutical worker from future interaction with the agency after she was convicted of lying during an investigation of her company, rejecting her bid for judicial review of the decision.

  • April 13, 2026

    Chamber, Other Biz Groups Back Insulin Cos. At High Court

    The U.S. Chamber of Commerce and other business groups urged the U.S. Supreme Court to take up an appeal from Sanofi-Aventis, Eli Lilly, Novo Nordisk and AstraZeneca, arguing the Second Circuit's revival of an antitrust suit risks opening up liability just for trade group membership.

  • April 13, 2026

    Ex-Med Spa Workers Settle Conn. Poaching Claims

    A Connecticut medical spa has settled a state court lawsuit accusing two former employees of luring clients and a colleague to a similar facility less than six miles away, court records show.

  • April 10, 2026

    Medtronic Can't Ax $382M Trial Loss, Applied Medical Says

    Applied Medical Resources Corp. has urged a California federal court to reject Medtronic Inc.'s attempt to ditch its roughly $382 million antitrust trial loss, arguing that Medtronic is simply repeating "erroneous legal arguments this court already rejected."

  • April 10, 2026

    Chest Binders Become Latest Front In Anti-Trans Litigation

    Chest binders — medical devices that can be used by individuals experiencing gender dysphoria or who want a more gender-neutral alternative to bras — have emerged as the newest target in an unfolding regulatory and legal climate that transgender advocates describe as an overtly partisan political attack against a type of product that the U.S. Food and Drug Administration has deemed the least risky.

  • April 10, 2026

    Chinese Scholar Gets Time Served For Smuggling E. Coli DNA

    A Chinese postdoctoral research associate at Indiana University was sentenced to time served on Wednesday by an Indiana federal judge, spending more than four months in custody on smuggling charges for shipping an E. coli sample from China into the U.S. and lying about it when questioned by U.S. Customs and Border Protection agents. 

Expert Analysis

  • Series

    Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief

    Author Photo

    My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.

  • 5 Drug Pricing Policy Developments To Watch In 2026

    Author Photo

    2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.

  • Patent Applicants Must Get Biologics Enablement Right

    Author Photo

    As artificial intelligence increasingly becomes a core driver in drug discovery, it is critical for drug companies to adapt their drafting strategies to the unique features of AI-generated inventions, and to pay particularly close attention to enablement standards, says Sanandan Malhotra at Novo Nordisk.

  • Series

    Law School's Missed Lessons: How To Start A Law Firm

    Author Photo

    Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.

  • Fed. Circ. Patent Decisions In 2025: An Empirical Review

    Author Photo

    In 2025, the Federal Circuit's increased output was not enough to keep up with its ever-growing patent case load, and patent owners and applicants fared poorly overall as the court's affirmance rate fell, says Dan Bagatell at Perkins Coie.

  • Regulatory Uncertainty Ahead For Organ Transplant System

    Author Photo

    Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.

  • Key False Claims Act Trends From The Last Year

    Author Photo

    The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.

  • Opinion

    It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs

    Author Photo

    The U.S. Food and Drug Administration's decision this month to order removal of warnings about the risk of suicidal thoughts from GLP-1 weight-loss drugs is premature — and from a safety and legal standpoint, the downside of acting too soon could be profound, says Sean Domnick at Rafferty Domnick.

  • Series

    Hosting Exchange Students Makes Me A Better Lawyer

    Author Photo

    Opening my home to foreign exchange students makes me a better lawyer not just because prioritizing visiting high schoolers forces me to hone my organization and time management skills but also because sharing the study-abroad experience with newcomers and locals reconnects me to my community, says Alison Lippa at Nicolaides Fink.

  • FDA's 2025 Enforcement Scorecard Highlights Data Focus

    Author Photo

    The U.S. Food and Drug Administration's increased enforcement activity in 2025 was driven by artificial intelligence and a focus on foreign manufacturers, necessitating proactive compliance strategies for an environment that is increasingly reliant on data, say attorneys at Reed Smith.

  • How A 1947 Tugboat Ruling May Shape Work Product In AI Era

    Author Photo

    Rapid advances in generative artificial intelligence test work-product principles first articulated in the U.S. Supreme Court’s nearly 80-year-old Hickman v. Taylor decision, as courts and ethics bodies confront whether disclosure of attorneys’ AI prompts and outputs would reveal their thought processes, say Larry Silver and Sasha Burton at Langsam Stevens.

  • Navigating Privilege Law Patchwork In Dual-Purpose Comms

    Author Photo

    Three years after the U.S. Supreme Court declined to resolve a circuit split in In re: Grand Jury, federal courts remain split as to when attorney-client privilege applies to dual-purpose legal and business communications, and understanding the fragmented landscape is essential for managing risks, say attorneys at Covington.

  • How AI Drafting Should Transform Patent Filing Strategies

    Author Photo

    As agentic artificial intelligence reduces the time and expense required to draft and file patents, companies should shift focus away from rationing drafting hours and more toward governing optionality, says Ian Schick at Paximal.

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.